Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: LIBRIUM
Published 2026-02-16 · Last reviewed 2026-02-23 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Chlordiazepoxide is a long-acting benzodiazepine indicated for the management of anxiety disorders (or short-term relief of anxiety symptoms), withdrawal symptoms of acute alcoholism, and preoperative apprehension/anxiety (label).
Long half-life can smooth withdrawal symptoms but increases accumulation and next-day impairment risk; it is not a good fit for chronic “PRN” anxiety prescribing.
Because of its long duration, chlordiazepoxide is sometimes used in structured withdrawal protocols or taper plans, but this should be paired with clear monitoring and stop dates; large outpatient quantities that drift into chronic use are generally avoided.
For alcohol withdrawal, use protocolized monitoring and taper as symptoms resolve; converting withdrawal regimens into chronic outpatient benzodiazepine therapy is generally avoided once the acute phase ends.
Co-prescribing with opioids and alcohol is generally avoided (boxed warning for opioid combinations), and fall and driving safety is reassessed at every renewal.
The chlordiazepoxide compare view, the chlordiazepoxide evidence feed, and the chlordiazepoxide print page can support safe-use counseling and shared decision-making.
Chlordiazepoxide is commonly used in alcohol withdrawal protocols due to its long half-life, but that same long half-life increases accumulation, falls, and delirium risk in older adults and with polypharmacy. Use protocolized monitoring, document taper/stop dates, and avoid chronic anxiety maintenance use.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Positive allosteric modulator of GABA-A receptors, producing anxiolytic, sedative, and anticonvulsant effects through increased inhibitory neurotransmission.
Long half-life can smooth symptom fluctuations but also increases carry-over sedation and cognitive slowing.
Tolerance and dependence can develop with repeated use; abrupt discontinuation after prolonged courses can produce withdrawal.
Sources: FDA/DailyMed label; ASAM alcohol withdrawal guideline; benzodiazepine safety guidance.